Your browser is no longer supported. Please, upgrade your browser.
DTIL [NASD]
Precision BioSciences, Inc.
Index- P/E- EPS (ttm)-2.10 Insider Own10.70% Shs Outstand52.55M Perf Week-7.59%
Market Cap481.10M Forward P/E- EPS next Y-1.89 Insider Trans-3.54% Shs Float44.80M Perf Month-3.65%
Income-109.00M PEG- EPS next Q-0.50 Inst Own50.80% Short Float14.19% Perf Quarter-42.69%
Sales24.30M P/S19.80 EPS this Y5.30% Inst Trans3.06% Short Ratio8.41 Perf Half Y28.13%
Book/sh0.85 P/B10.10 EPS next Y8.30% ROA-60.80% Target Price- Perf Year18.25%
Cash/sh1.60 P/C5.36 EPS next 5Y- ROE-141.20% 52W Range4.45 - 16.60 Perf YTD2.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.28% Beta-
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low92.70% ATR0.61
Employees231 Current Ratio2.50 Sales Q/Q35.40% Oper. Margin- RSI (14)40.86 Volatility6.27% 6.77%
OptionableYes Debt/Eq0.00 EPS Q/Q65.70% Profit Margin- Rel Volume0.62 Prev Close8.42
ShortableYes LT Debt/Eq0.00 EarningsMay 13 BMO Payout- Avg Volume756.42K Price8.59
Recom1.80 SMA20-4.39% SMA50-14.71% SMA200-3.06% Volume467,174 Change1.96%
Jul-27-20Resumed BTIG Research Buy $16
Apr-03-20Downgrade Goldman Buy → Neutral $24 → $7
Mar-05-20Initiated Stifel Buy $21
Feb-25-20Initiated William Blair Outperform
Aug-09-19Initiated BTIG Research Buy $22
Jul-16-19Initiated H.C. Wainwright Buy $21
Apr-22-19Initiated JP Morgan Overweight
Apr-22-19Initiated Jefferies Buy
Apr-22-19Initiated Goldman Buy
Apr-22-19Initiated Barclays Overweight
May-06-21 07:00AM  
May-03-21 07:00AM  
Apr-29-21 04:40AM  
Apr-27-21 04:35PM  
Apr-15-21 04:36PM  
04:10PM  
Apr-12-21 07:06AM  
Apr-09-21 04:05PM  
Apr-06-21 08:35AM  
Mar-29-21 07:00AM  
Mar-18-21 09:08AM  
08:35AM  
07:34AM  
07:00AM  
Mar-12-21 07:00AM  
Mar-02-21 12:30PM  
07:00AM  
Feb-19-21 08:32AM  
07:00AM  
Feb-11-21 01:36AM  
Feb-04-21 07:00AM  
Jan-25-21 07:00AM  
Jan-20-21 09:47AM  
Jan-19-21 07:00AM  
Jan-07-21 07:00AM  
Jan-04-21 07:00AM  
Dec-14-20 09:10PM  
12:00AM  
Dec-11-20 11:00AM  
Dec-04-20 06:30AM  
Nov-24-20 04:05PM  
Nov-20-20 07:00AM  
Nov-13-20 06:12AM  
Nov-10-20 08:45AM  
07:28AM  
07:00AM  
Nov-03-20 12:30PM  
07:00AM  
Oct-15-20 07:00AM  
Oct-14-20 07:00AM  
Sep-28-20 07:00AM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 07:21AM  
Sep-09-20 07:00AM  
Sep-02-20 07:00AM  
Aug-19-20 07:00AM  
Aug-13-20 10:35AM  
07:30AM  
07:00AM  
Aug-06-20 12:30PM  
Aug-03-20 07:00AM  
Jul-17-20 10:29AM  
Jul-06-20 07:00AM  
Jul-05-20 04:33PM  
Jun-08-20 07:00AM  
May-26-20 04:01PM  
May-18-20 06:34AM  
May-15-20 08:52AM  
08:15AM  
07:00AM  
May-08-20 12:30PM  
May-07-20 07:00AM  
Apr-28-20 04:45PM  
Apr-27-20 12:31PM  
Apr-15-20 07:00AM  
Apr-07-20 07:00AM  
Apr-02-20 02:54PM  
Mar-12-20 07:26AM  
Mar-11-20 07:24AM  
07:00AM  
Mar-10-20 07:05AM  
Feb-21-20 07:00AM  
Jan-13-20 07:00AM  
Jan-06-20 07:00AM  
Dec-31-19 03:15PM  
07:25AM  
Dec-30-19 03:40PM  
Dec-19-19 06:28PM  
Dec-09-19 04:19PM  
08:42AM  
07:00AM  
Nov-27-19 09:24AM  
Nov-13-19 07:00AM  
Nov-12-19 07:15AM  
Nov-06-19 09:01AM  
Oct-31-19 12:20PM  
Oct-30-19 10:34AM  
06:30AM  
Oct-03-19 10:11AM  
Sep-30-19 07:58AM  
06:30AM  
Sep-26-19 06:30AM  
Sep-23-19 06:30AM  
Sep-17-19 07:10AM  
Sep-16-19 06:30AM  
Sep-04-19 06:30AM  
Aug-28-19 06:30AM  
Aug-14-19 04:30PM  
11:37AM  
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KANE MATTHEW R.President and CEOApr 21Option Exercise1.1813,42215,8381,978,218Apr 23 04:06 PM
JANTZ DEREKChief Scientific OfficerApr 19Option Exercise0.0421,5148614,026,435Apr 21 04:11 PM
JANTZ DEREKChief Scientific OfficerApr 19Sale8.699,67684,0844,016,759Apr 21 04:11 PM
JANTZ DEREKChief Scientific OfficerApr 16Option Exercise0.0421,5148614,014,596Apr 19 04:06 PM
JANTZ DEREKChief Scientific OfficerApr 16Sale8.849,67585,5274,004,921Apr 19 04:06 PM
JANTZ DEREKChief Scientific OfficerApr 15Option Exercise0.0421,5148614,002,758Apr 19 04:06 PM
JANTZ DEREKChief Scientific OfficerApr 15Sale8.769,67684,7623,993,082Apr 19 04:06 PM
KANE MATTHEW R.President and CEOApr 12Option Exercise0.0421,5148611,974,537Apr 14 04:37 PM
KANE MATTHEW R.President and CEOApr 12Sale8.679,74184,4541,964,796Apr 14 04:37 PM
KANE MATTHEW R.President and CEOApr 09Option Exercise0.0421,5148611,962,760Apr 12 05:06 PM
KANE MATTHEW R.President and CEOApr 09Sale8.879,73786,3671,953,023Apr 12 05:06 PM
KANE MATTHEW R.President and CEOApr 08Option Exercise0.0421,5148611,950,982Apr 12 05:06 PM
KANE MATTHEW R.President and CEOApr 08Sale9.009,73687,6241,941,246Apr 12 05:06 PM
JANTZ DEREKChief Scientific OfficerMar 18Option Exercise0.0421,5148613,990,909Mar 22 04:12 PM
JANTZ DEREKChief Scientific OfficerMar 18Sale11.089,665107,0883,981,244Mar 22 04:12 PM
JANTZ DEREKChief Scientific OfficerMar 17Option Exercise0.0421,5148613,979,060Mar 18 04:05 PM
JANTZ DEREKChief Scientific OfficerMar 17Sale10.929,665105,5423,969,395Mar 18 04:05 PM
JANTZ DEREKChief Scientific OfficerMar 16Option Exercise0.0421,5148613,967,207Mar 18 04:05 PM
JANTZ DEREKChief Scientific OfficerMar 16Sale11.979,661115,6423,957,546Mar 18 04:05 PM
KANE MATTHEW R.President and CEOMar 12Option Exercise0.0421,5148611,939,180Mar 16 04:34 PM
KANE MATTHEW R.President and CEOMar 12Sale11.369,712110,3281,929,468Mar 16 04:34 PM
KANE MATTHEW R.President and CEOMar 11Option Exercise0.0421,5148611,927,377Mar 12 06:03 PM
KANE MATTHEW R.President and CEOMar 11Sale11.389,711110,5111,917,666Mar 12 06:03 PM
KANE MATTHEW R.President and CEOMar 10Option Exercise0.0421,5148611,915,573Mar 12 06:03 PM
KANE MATTHEW R.President and CEOMar 10Sale11.799,710114,4811,905,863Mar 12 06:03 PM
JANTZ DEREKChief Scientific OfficerFeb 22Option Exercise0.0421,5148613,955,353Feb 24 05:46 PM
JANTZ DEREKChief Scientific OfficerFeb 22Sale12.049,660116,3063,945,693Feb 24 05:46 PM
JANTZ DEREKChief Scientific OfficerFeb 19Option Exercise0.0421,5148613,943,502Feb 22 07:03 PM
JANTZ DEREKChief Scientific OfficerFeb 19Sale11.559,663111,6083,933,839Feb 22 07:03 PM
KANE MATTHEW R.President and CEOFeb 18Option Exercise0.0421,5148611,899,151Feb 22 04:45 PM
JANTZ DEREKChief Scientific OfficerFeb 18Option Exercise0.0421,5148613,928,859Feb 22 07:03 PM
JANTZ DEREKChief Scientific OfficerFeb 18Sale12.206,87183,8263,921,988Feb 22 07:03 PM
KANE MATTHEW R.President and CEOFeb 18Sale12.239,705118,6921,889,446Feb 22 04:45 PM
KANE MATTHEW R.President and CEOFeb 17Option Exercise0.0421,5148611,887,342Feb 18 04:44 PM
KANE MATTHEW R.President and CEOFeb 17Sale12.289,705119,1771,877,637Feb 18 04:44 PM
KANE MATTHEW R.President and CEOFeb 16Option Exercise0.0421,5148611,875,525Feb 18 04:44 PM
KANE MATTHEW R.President and CEOFeb 16Sale13.309,697128,9701,865,828Feb 18 04:44 PM
JANTZ DEREKChief Scientific OfficerJan 29Option Exercise0.0421,5158613,913,789Feb 02 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 29Sale12.256,44478,9393,907,345Feb 02 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 28Option Exercise0.0421,5148613,898,718Jan 29 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 28Sale11.976,44477,1353,892,274Jan 29 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 27Option Exercise0.0421,5148613,884,252Jan 29 05:00 PM
JANTZ DEREKChief Scientific OfficerJan 27Sale11.687,04882,3213,877,204Jan 29 05:00 PM
KANE MATTHEW R.President and CEOJan 26Option Exercise0.0421,5158611,863,708Jan 28 04:00 PM
KANE MATTHEW R.President and CEOJan 26Sale13.379,697129,6491,854,011Jan 28 04:00 PM
KANE MATTHEW R.President and CEOJan 25Option Exercise0.0421,5148611,851,888Jan 26 04:56 PM
KANE MATTHEW R.President and CEOJan 25Sale13.749,695133,2091,842,193Jan 26 04:56 PM
KANE MATTHEW R.President and CEOJan 22Option Exercise0.0421,5148611,840,592Jan 26 04:56 PM
KANE MATTHEW R.President and CEOJan 22Sale13.5310,218138,2501,830,374Jan 26 04:56 PM
THOMSON DAVID S.Chief Operating OfficerJan 21Sale16.4910,000164,900109,243Jan 25 08:00 AM
ANSARI ABIDChief Financial OfficerJun 15Option Exercise1.208,78310,540144,401Jun 17 04:00 PM
ANSARI ABIDChief Financial OfficerMay 15Option Exercise1.209,66111,576135,618May 19 07:17 AM